BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables)

3 Months Ended

Dec. 31, 2020

BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES

Schedule of operations and timing of revenue recognition

The following table presents revenues disaggregated by our business operations and timing of revenue recognition:

	Three Month Period Ended:
	December 31,		December 31,
	2020		2019
Research and development services (over-time)	$	263,713	$	366,834
Clinical laboratory testing services (point-in-time)		772,770		—
Product and authentication services (point-in-time):
Supply chain		32,942		18,674
Asset marking		151,758		108,572
Large scale DNA production		—		139,439
Diagnostic kits		394,958		—
Total	$	1,616,141	$	633,519

Schedule of opening and closing contract balances

The opening and closing balances of the Company’s contract balances are as follows:

		October 1,		December 31,		$
	Balance sheet classification	2020		2020		change
Contract liabilities	Deferred revenue	$	511,036	$	364,831	$	146,205

Schedule of anti-dilutive securities not included computation of net loss per share

	2020	2019
Warrants	778,118	2,692,798
Stock options	358,178	220,241
Secured convertible notes	—	70,963
Total	1,136,296	2,984,002